ImCheck Therapeutics

Health & Care

Company profile

ImCheck Therapeutics was founded in 2015 as a spin-off from the Paoli-Calmettes Cancer Institute in Marseille (France). The biotech company is developing innovative antibody therapeutics in the field of immuno-oncology, based on scientific assets originating from the pioneering work of Prof. Daniel Olive.


Investment rationale

ImCheck Therapeutics is an emerging player in the field of cancer and auto-immune immunotherapies that focuses on the development of first-in-class antibodies that activate the immune system against different cancer types. Gimv strongly believes in the company because of the game-changing potential of ImCheck’s development candidates for the treatment of cancer.

Growth strategy

The funds will be used to advance its lead candidates towards clinical development, as well as to progress its discovery programs.
Our previous investments in Topas Therapeutics, G-Therapeutics, Endostim, Spineart and Breath Therapeutics will allow us to help ImCheck Therapeutics in realizing its ambitions.

ImCheck Therapeutics

Karl Nägler, Partner

Karl Nägler joined Gimv in 2011.

Having started his professional career in 2002 at Atlas Venture in London and Munich, he later joined Ventech, a Paris-based venture capital firm focused on Europe and China.

Karl has a successful track record in early and later stage Life Science investing and was instrumental in the formation, financing and/or exit of several start-ups across Europe, including U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (acquired by Horizon Pharma, HZNP:US), Egalet (EGLT:US), Funxional Therapeutics (acquired by Boehringer Ingelheim) and Themis.

Since he joined Gimv, Karl has led investments into Prosonix (acquired by Circassia, CIR:LN), Covagen (acquired by Johnson & Johnson, JNJ:US), Biom'up (BUP:EPA), Topas Therapeutics, Breath Therapeutics and Imcheck Therapeutics and has represented Gimv on the boards of those companies as well as on the board of Actogenix (acquired by Intrexon, XON:US).

Previously, Karl had worked as a Scientific Fellow at the CNRS for Neurochemistry in Strasbourg (France) and holds a PhD in the area of molecular neurobiology from the Max-Delbrück-Center for Molecular Medicine (Berlin) and a Diploma in Biology from the Free University of Berlin.


+49 89 4423 275 50

Promenadeplatz 12
80333 München


Karl Nägler